Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 14/20 | 0.51 |
| ▸ | MMP9 | P14780 | 13/20 | 0.51 |
| ▸ | MMP1 | P03956 | 13/20 | 0.51 |
| ▸ | ADAM17 | P78536 | 8/20 | 0.51 |
| ▸ | DUT | P33316 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 5/20 | 0.40 |
| ▸ | MMP3 | P08254 | 3/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | MMP14 | P50281 | 1/20 | 0.37 |
| ▸ | MMP16 | P51512 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7532360 | 1.00 | MMP13 (0.51) | MMP13MMP9MMP1ADAM17DUT | |
| SCHEMBL7533478 | 0.92 | MMP13 (0.53) | MMP13MMP9MMP1ADAM17DUT | |
| SCHEMBL7533476 | 0.92 | MMP13 (0.53) | MMP13MMP9MMP1ADAM17DUT | |
| SCHEMBL7540502 | 0.92 | MMP13 (0.51) | MMP13MMP9MMP1ADAM17DUT | |
| SCHEMBL7540496 | 0.92 | MMP13 (0.51) | MMP13MMP9MMP1ADAM17DUT | |
| SCHEMBL7539581 | 0.84 | MMP9 (0.44) | MMP13MMP9MMP1ADAM17DUT | |
| SCHEMBL7533819 | 0.84 | MMP9 (0.44) | MMP13MMP9MMP1ADAM17DUT | |
| SCHEMBL7534007 | 0.83 | MMP13 (0.54) | MMP13MMP9MMP1ADAM17DUT | |
| SCHEMBL7534005 | 0.83 | MMP13 (0.54) | MMP13MMP9MMP1ADAM17DUT | |
| SCHEMBL7533025 | 0.80 | MMP9 (0.44) | MMP13MMP9MMP1ADAM17DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-H1992-H1 | INHIBITION OF METALLOPROTEINASES AND TUMOR NECROSIS FACTOR CONVERTASE WHICH DEGRADE PROTEIN COMPONENTS OF EXTRACELLULAR MATRIX | AGOURON PHARMACEUTICALS, INC. | 2001-09-04 | — | — | US | claimed |
| US-H1992-H1 | INHIBITION OF METALLOPROTEINASES AND TUMOR NECROSIS FACTOR CONVERTASE WHICH DEGRADE PROTEIN COMPONENTS OF EXTRACELLULAR MATRIX | AGOURON PHARMACEUTICALS, INC. | 2001-09-04 | — | — | US | disclosed |
| WO-1998050348-A1 | METALLOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PHARMACEUTICAL USES | AGOURON PHARMACEUTICALS, INC. (US) | 1998-11-12 | — | — | WO | disclosed |